Preliminary results of the first COVID-19 vaccine to enter the human body for trial to prevent the outbreak of the new novel coronavirus are impressive.
The US company Moderna launched the first vaccine for experiment to prevent the coronavirus, MRNA 1273, on humans in March, and now, about two months later, preliminary results have emerged.
The vaccine was tested on a few people in the first phase, and now the company says it has developed an immune response seen in patients who have recovered from COVID-19.
The company’s chief medical officer said that the results of this provisional Phase 1 data are preliminary, but it shows that people who have been vaccinated have developed an immune response that helps fight the virus.
The company claims that the vaccine is safe and does not cause patients to experience redness or swelling of the skin.
Moderna’s CEO Stephen Bancel said in a conference call that preliminary results showed confidence that the vaccine would provide protection against the virus.
In the first phase of the trial, people aged 18 to 55 were given three different doses of the vaccine, the full results of which have not yet been released.
The trial of the second phase of the vaccine was approved by the US Food and Drug Administration (FDA) this month and work will begin in the next few weeks.
The third phase of the trial will be the most important, working to prove the effectiveness of the vaccine, and will begin in July.
According to the company’s CEO, the research team’s focus is on launching the third phase as early as July.
Following the partial results of the first phase, the company also says that it is not researching higher doses because even lower doses are causing positive effects.
Millions of people will be hired for the third phase to determine if the vaccine is effective and does not cause any harm.
After the third phase, the FDA will decide to approve the use of this vaccine and this approval will be given only if it proves to be safe and effective while its benefits outweigh the risks.
Human trials of the vaccine are also underway in China, Britain and Germany.
Several companies, including Moderna, have announced that they will begin mass production of the vaccine after all clinical trials will be completed.
Moderna has announced a partnership with Lonza, a major pharmaceutical company, for this purpose, with the potential to produce one billion doses a year.